|
|
MPL |
|
Vaxjo ID |
327 |
|
Vaccine Adjuvant Name |
MPL |
|
Description |
GRA2 is a recombinant dense granule antigen of *Toxoplasma gondii*. MPL is monophosphoryl lipid A, an adjuvant. |
|
Stage of Development |
Research |
|
Host Species for Testing |
Mouse |
|
Components |
We aimed to examine whether immunization of a distinct strain of rodent with recombinant dense granule antigens (GRA2) combined with monophosphorryl lipid A (MPL) adjuvant elicits protective immune response against T. |
|
Preparation |
The paper mentions "recombinant dense granule antigens (GRA2)" formulated in "MPL adjuvant", but detailed preparation steps are not provided. |
|
Function |
Three weeks after immunization with GRA2, mice showed strong IgG1 and IFN-γ responses and significantly fewer brain cysts than controls. However, four months later, despite strong antibodies, IFN-γ levels and cyst reduction were not significant. Engages TLR4 pathway to promote Th1 responses. [PMC10067403] |
| References |
Babaie et al., 2018: Babaie J, Amiri S, Homayoun R, Azimi E, Mohabati R, Berizi M, Sadaie MR, Golkar M. Immunization of C57BL/6 Mice with GRA2 Combined with MPL Conferred Partial Immune Protection against Toxoplasma gondii. Iranian biomedical journal. 2018; 22(1); 22-32. [PubMed: 28646827].
|
|
